The much-touted multiple sclerosis drug from Biogen Idec Inc., which pumped investors' hopes and then bombed, continues to grab headlines, albeit smaller ones. The drug was pulled from the market in February after it was linked to patient deaths from progressive multifocal leukoencephalopathy.
Genentech Inc. got the green light to expand its growth hormone market, as the FDA approved Nutropin (somatropin [rDNA origin] for injection) and Nutropin AQ (somatropin [rDNA origin] injection) for the long-term treatment of idiopathic short stature (ISS). (BioWorld Today)
RSS